Ironwood Pharmaceuticals reported $33.33M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.


Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
Almirall EUR 91.3M 55.52M Mar/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amarin USD 36.57M 397K Mar/2025
Ardelyx USD 83.99M 7.92M Jun/2025
Astellas Pharma JPY 197B 14.32B Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Charles River Laboratories USD 185.82M 8.02M Jun/2025
Exact Sciences USD 455.7M 29.3M Jun/2025
Halozyme Therapeutics USD 33M 9.36M Jun/2025
Incyte USD 331.02M 5.33M Jun/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
MacroGenics USD 9.3M 18.51M Jun/2025
Moderna USD 230M 18M Jun/2025
Myriad Genetics USD 135.7M 300K Mar/2025
Pacira USD 77.19M 9.58M Jun/2025
PTC Therapeutics USD 85.26M 76.66M Jun/2025
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
Takeda JPY 255.89B 39.98B Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025